JP2002540767A - エポキシドヒドロラーゼ複合体とそれを用いた方法 - Google Patents

エポキシドヒドロラーゼ複合体とそれを用いた方法

Info

Publication number
JP2002540767A
JP2002540767A JP2000599385A JP2000599385A JP2002540767A JP 2002540767 A JP2002540767 A JP 2002540767A JP 2000599385 A JP2000599385 A JP 2000599385A JP 2000599385 A JP2000599385 A JP 2000599385A JP 2002540767 A JP2002540767 A JP 2002540767A
Authority
JP
Japan
Prior art keywords
compound
epoxide hydrolase
sulfur
epoxide
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000599385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540767A5 (https=
Inventor
ブルース、 ディー． ハモック、
クリストフ、 エイチ． モリソー、
ジアン ジォン、
マーヴィン、 エイチ． グッドロウ、
トーニャ セヴァーソン、
ジェームズ サンボーン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2002540767A publication Critical patent/JP2002540767A/ja
Publication of JP2002540767A5 publication Critical patent/JP2002540767A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2000599385A 1999-02-18 2000-02-10 エポキシドヒドロラーゼ複合体とそれを用いた方法 Pending JP2002540767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/252,148 1999-02-18
US09/252,148 US6150415A (en) 1996-08-13 1999-02-18 Epoxide hydrolase complexes and methods therewith
PCT/US2000/003495 WO2000048593A1 (en) 1999-02-18 2000-02-10 Epoxide hydrolase complexes and methods therewith

Publications (2)

Publication Number Publication Date
JP2002540767A true JP2002540767A (ja) 2002-12-03
JP2002540767A5 JP2002540767A5 (https=) 2007-03-29

Family

ID=22954799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000599385A Pending JP2002540767A (ja) 1999-02-18 2000-02-10 エポキシドヒドロラーゼ複合体とそれを用いた方法

Country Status (10)

Country Link
US (1) US6150415A (https=)
EP (2) EP1844767B1 (https=)
JP (1) JP2002540767A (https=)
AT (1) ATE375153T1 (https=)
AU (1) AU3360800A (https=)
CA (1) CA2362331C (https=)
DE (1) DE60036690T2 (https=)
DK (1) DK1154764T3 (https=)
ES (1) ES2291196T3 (https=)
WO (1) WO2000048593A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6562563B1 (en) 1999-11-03 2003-05-13 Mitokor Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002082082A2 (en) * 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6756210B2 (en) * 2001-05-29 2004-06-29 The Regents Of The University Of California Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
GB0214342D0 (en) * 2002-06-21 2002-07-31 Givaudan Sa Insect repellents
EP1558591B1 (en) 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20050164951A1 (en) * 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
EP1765311A4 (en) * 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1885361A2 (en) * 2005-05-06 2008-02-13 Boehringer Ingelheim International GmbH Acyl hydrazones for treating cardiovascular diseases
WO2006121719A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
JP2009504785A (ja) * 2005-08-19 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎮痛剤としてのｓＥＨ阻害剤の使用
CA2622754A1 (en) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
RU2453556C2 (ru) 2005-11-09 2012-06-20 Протеоликс, Инк. Соединения для ингибирования фермента
WO2007079593A1 (en) * 2006-01-13 2007-07-19 Mcgill University Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
CA2643859A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
EP2124928A4 (en) * 2006-12-15 2011-01-05 Univ California USE OF CIS EPOXY EICOSATRIC ACIDS AND INHIBITORS OF SOLUBLE EPOXY HYDROLASE FOR THE TREATMENT OF DISEASES CAUSED BY PBR, CB2 AND NK
CA2671837A1 (en) * 2006-12-18 2008-06-26 F. Hoffmann-La Roche Ag Novel use of inhibitors of soluble epoxide hydrolase
US8455520B2 (en) * 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009020960A1 (en) 2007-08-06 2009-02-12 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
KR20170040374A (ko) 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2259680A4 (en) * 2008-03-04 2012-01-25 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
US9029401B2 (en) 2011-02-14 2015-05-12 The Regents Of The University Of California Sorafenib derivatives as sEH inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN104093708B (zh) 2012-02-01 2016-11-09 加利福尼亚大学董事会 可溶性环氧化物水解酶的酰基哌啶抑制剂
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
US20200317813A1 (en) 2016-05-25 2020-10-08 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Treatment and diagnosis of non-proliferative diabetic retinopathy
WO2020074549A1 (en) 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
EP3877519B1 (en) 2018-11-09 2026-03-11 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215420A (ja) * 1989-06-08 1991-09-20 Procter & Gamble Co:The 呼吸疾患又は障害の治療に関するバニロイド類の用途
JPH04270255A (ja) * 1990-02-26 1992-09-25 Merrell Dow Pharmaceut Inc 酸化窒素生合成の抑制剤
JPH08301840A (ja) * 1995-03-07 1996-11-19 Santen Pharmaceut Co Ltd Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体
WO1998006261A1 (en) * 1996-08-13 1998-02-19 The Regents Of The University Of California Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1056290A (en) * 1963-05-06 1967-01-25 Du Pont Dicycloalkyl ureas
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215420A (ja) * 1989-06-08 1991-09-20 Procter & Gamble Co:The 呼吸疾患又は障害の治療に関するバニロイド類の用途
JPH04270255A (ja) * 1990-02-26 1992-09-25 Merrell Dow Pharmaceut Inc 酸化窒素生合成の抑制剤
JPH08301840A (ja) * 1995-03-07 1996-11-19 Santen Pharmaceut Co Ltd Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体
WO1998006261A1 (en) * 1996-08-13 1998-02-19 The Regents Of The University Of California Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤

Also Published As

Publication number Publication date
ES2291196T3 (es) 2008-03-01
AU3360800A (en) 2000-09-04
EP1154764A4 (en) 2005-02-16
EP1154764B1 (en) 2007-10-10
EP1844767B1 (en) 2012-08-29
DE60036690D1 (de) 2007-11-22
ATE375153T1 (de) 2007-10-15
DK1154764T3 (da) 2008-02-04
EP1844767A2 (en) 2007-10-17
EP1154764A1 (en) 2001-11-21
CA2362331C (en) 2010-04-20
CA2362331A1 (en) 2000-08-24
WO2000048593A1 (en) 2000-08-24
DE60036690T2 (de) 2008-07-17
EP1844767A3 (en) 2010-01-13
US6150415A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
JP2002540767A (ja) エポキシドヒドロラーゼ複合体とそれを用いた方法
US20060035869A1 (en) Inhibitors of epoxide hydrolases for the treatment of hypertension
Vandiver et al. Hydrogen sulfide: a gasotransmitter of clinical relevance
Nagatsu Progress in monoamine oxidase (MAO) research in relation to genetic engineering
Baxter et al. Elevation of γ-aminobutyric acid in brain: selective inhibition of γ-aminobutyric-α-ketoglutaric acid transaminase
Shen Prostaglandin synthetase inhibitors I
Ricciardolo et al. Nitric oxide in health and disease of the respiratory system
Moncada et al. The discovery of nitric oxide as the endogenous nitrovasodilator.
US5955496A (en) Dihydroxy-oxy-eicosadienoates
Graf et al. Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue
US20030149082A1 (en) Inhibitors of the anandamide transporter as analgesic agents
McMillan Leukotrienes in respiratory disease
Hospattankar et al. Changes in liver lipids after administration of 2-decanoylamino-3-morpholinopropiophenone and chlorpromazine
Kose et al. The human carbonic anhydrase isoenzymes I and II inhibitory effects of some hydroperoxides, alcohols, and acetates
Avner et al. Desensitization of isolated human bronchial smooth muscle to β-receptor agonists
DuBois et al. Quantitative measurement of inhibition of aliesterases, acylamidase, and cholinesterase by EPN and Delnav®
Hwang et al. Isodihydrocapsiate stimulates plasma glucose uptake by activation of AMP-activated protein kinase
Peana et al. Is catalase involved in the effects of systemic and pVTA administration of 4-methylpyrazole on ethanol self-administration?
US6809116B2 (en) Materials and methods for the treatment of depression
HK1109591A (en) Epoxide hydrolase complexes and methods therewith
Hunter Nitric oxide, inducible nitric oxide synthase and inflammation in veterinary medicine
Tawa et al. Impairment by Hypoxia or Hypoxia/Reoxygenation of Nitric Oxide–Mediated Relaxation in Isolated Monkey Coronary Artery: the Role of Intracellular Superoxide
Belvisi et al. Nitric oxide as a biological mediator
Mehler et al. Biological reactions of fluoroacetylcholine
Echizen et al. Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100427